ArticleBlood vessels, thrombosis & hemostasis2026
The role of hemoglobin F in sickle cell disease complications: a descriptive secondary analysis.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Platelet-to-Neutrophil Ratio as a Biomarker for Pulmonary Hypertension in Sickle Cell Disease Patients: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with sickle cell disease (SCD), a prevalent inherited blood disorder, are at increased risk for tissue ischemia and thrombosis secondary to sickle hemoglobin polymerization. Fetal hemoglobin (HbF) protects against the vaso-occlusive nature of sickled erythrocytes. Our study aims to investigate the association between HbF level and various SCD complications. The study used a descriptive and cross-sectional design to analyze existing, secondary medical record data of 496 patients with SCD who received care from the Center for Blood Disorders in Augusta, Georgia. Of these, only patients with HbSS and an HbSβ0 thalassemia (n = 273) were included in the analysis. Data abstraction included history of thrombotic event (TE) and HbF values closest to the TE, along with presence of SCD clinical complications, use of anticoagulation medications, specific laboratory values, and Hb electrophoresis. These patients were reflective of the greater population of patients with SCD in that they had similar rates of complications such as avascular necrosis and sickle cell retinopathy compared with nationally reported data. We found a significant association between incidence of thrombosis and higher HbF levels (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.